FDA approval and launch plans for thyroid eye disease therapy drive strong investor interest.
What changed
VIRIDIAN THERAPEUTICS, INC. (VRDN) DISCUSSES FDA APPROVAL AND LAUNCH PLANS FOR LUMVOA AS A NEW THERAPY FOR THYROID EYE DISEASE TRANSCRIPT - SEEKINGALPHA